|
Clinical and Histopathological data from HIV/HPV co-infected woman |
|||
| Histopathology |
CIN I n = 14 |
CIN II/III/Ca n = 23 |
All N = 37 |
|
|
|||
| Log V. load |
|||
| Mean (SD) |
2.73 (1.42) |
1.98 (1.35) |
2.29 (1.40) |
| Median(IQR*) |
1.90 (1.89–4.2) |
1.84 (0.67–3.21) |
1.89 (0.70–3.68) |
| Not available |
5 (35.7%) |
11 (47.8%) |
15 (40.5%) |
| CD4 |
|||
| Mean(SD) |
336.3 (275.8) |
269.1 (99.3) |
300.7 (198.5) |
| Median(IQR*) |
217.5 (107–571) |
249 (220–344) |
249 (150–383) |
| Not available |
6 (42.8%) |
14 (60.8%) |
20 (54.0%) |
| CD8 |
|||
| Mean(SD) |
953.6 (338.8) |
685.8 (214.5) |
850.6 (317.3) |
| Median(IQR*) |
980(743–1241) |
619(509–896) |
958(564–1061) |
| Not available |
6(42.8%) |
18(78.2) |
24(64.8%) |
| Age |
|||
| Mean(SD) |
37.3 (7.12) |
35 (7.6) |
36.0 (7.4) |
| Median(IQR*) |
38(33–42) |
35(30–44) |
36.5(31–42.7) |
| Not available |
1(7%) |
0(0%) |
1(2.7%) |
| ARV |
|||
| HAART |
3(21.4%) |
7(30.4%) |
10(27%) |
| Mono/Dual |
2(14.3%) |
4 (17.4%) |
6(16.2%) |
| No use |
8(57.1%) |
11(47.8%) |
19(51.4%) |
| Not available |
1(7.1%) |
1(4.3%) |
2(5.4%) |
|
*IQR: Interquartile Range | |||
Nicol et al. BMC Cancer 2008 8:289 doi:10.1186/1471-2407-8-289 |
|||